Phage display technology and its impact in the discovery of novel protein-based drugs

• Published in: Expert opinion on drug discovery Vol. 19; no. 8; p. 887
• Main Authors: Hutchings, Catherine J, Sato, Aaron K
• Format: Journal Article
• Language: English
• Published: England 02.08.2024
• Subjects: Animals; Antibodies; Artificial Intelligence; Biotechnology - methods; Cell Surface Display Techniques - methods; Drug Development - methods; Drug Discovery - methods; Humans; Peptide Library; Peptides - chemistry; Peptides - pharmacology; Proteins; libraries; Phage display; peptide; alternative scaffolds; antibody; Next-Generation Sequencing (NGS)
• ISSN: 1746-045X
• DOI: 10.1080/17460441.2024.2367023

Phage display technology is a well-established versatile display technology that has been used for over 35 years to identify peptides and antibodies for use as reagents and therapeutics, as well as exploring the diversity of alternative scaffolds as another option to conventional therapeutic antibody discovery. Such successes have been responsible for spawning a range of biotechnology companies, as well as many complementary technologies devised to expedite the drug discovery process and resolve bottlenecks in the discovery workflow. In this perspective, the authors summarize the application of phage display for drug discovery and provide examples of protein-based drugs that have either been approved or are being developed in the clinic. The amenability of phage display to generate functional protein molecules to challenging targets and recent developments of strategies and techniques designed to harness the power of sampling diverse repertoires are highlighted. Phage display is now routinely combined with cutting-edge technologies to deep-mine antibody-based repertoires, peptide, or alternative scaffold libraries generating a wealth of data that can be leveraged, e.g. via artificial intelligence, to enable the potential for clinical success in the discovery and development of protein-based therapeutics.